로딩 중…
지수 로딩 중…
Celldex Therapeutics, Inc.
CLDX· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$37.69-0.97%
2026-08-03
Financials
Valuation Metrics
Celldex Therapeutics, Inc.'s Market Cap is $2.96B. At end of 2025 it was $1.81B. Ranked #1775 of 3,112 in US market (top 57%), #634 of 1,445 on NASDAQ (top 44%), #106 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 39%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.96B | US#1,775/3,112 Sec#106/269 |
| Revenue | $820000.00 | US#2,963/3,112 Sec#200/269 |
| Net Income | $-284M | US—/3,112 Sec—/269 |
| Total Assets | $511M | US#2,733/3,112 Sec#153/269 |
| Net Assets | $456M | US#2,321/3,112 Sec#120/269 |
| Value | ||
| P/B | 6.48x | US#2,365/3,112 Sec#165/269 |
| P/S | 1972.24x | US#2,956/3,112 Sec#201/269 |
| FCF Yield | -7.64% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -62.18% | US#2,781/3,112 Sec#192/269 |
| ROA | -55.49% | US#2,985/3,112 Sec#229/269 |
| Op. Margin | -37694.63% | US#2,969/3,112 Sec#201/269 |
| Revenue Growth | -97.84% | US#2,941/3,112 Sec#187/269 |
| Financial Health | ||
| Debt Ratio | 12.06% | US#134/3,112 Sec#58/269 |
| Total Debt | $2M | US#2,908/3,112 Sec#235/269 |
| FCF | $-226M | US#2,749/3,112 Sec#225/269 |
| Cash | $36M | US#2,713/3,112 Sec#244/269 |
| Current Ratio | 8.92x | US#279/3,112 Sec#90/269 |
| Performance | ||
| 1Y Return | 69.85% | US#465/3,112 Sec#101/269 |
| 1M Return | -1.77% | US#1,884/3,112 Sec#96/269 |
| From 52W High | -6.48% | US#706/3,112 Sec#27/269 |
| 1Y MDD | -24.23% | US#984/3,112 Sec#52/269 |
| Trading | ||
| Volume | 1,588,548 shares | US#1,075/3,112 Sec#97/269 |
| Trading Value | $60M | US#1,243/3,112 Sec#72/269 |
| Per Share | ||
| EPS | $-3.89 | US—/3,112 Sec—/269 |
| BPS | $7.93 | US#1,948/3,112 Sec#87/269 |